CDKN2B and neoplasm: Three major cancer associated pathways were affected in this somatic profile: the activation of the MAPK and phosphoinositide 3-kinase (PI3K) signaling pathways, BRAF and PIK3CA mutations, respectively, and the inactivation of the tp53 tumor suppressor pathway with the CDKN2A and CDKN2B deletion.